Skip to main content
OpenTrials
Completed

NCT Number: NCT04706000

Autophagy Markers in Endometrial Polyps

The aim of this research is to evaluate autophagy markers in patients with endometrial polyps

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Endometrial Polyp Autophagy Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Polyps

Age range

35 year and older

Sex eligibility

Female

Study type

Observational

Primary location

Mugla Sıtkı Kocman University Faculty of Medicine

Muğla, 48000, Turkey (Türkiye)

About this study

Endometrial polyp are benign formations that are frequently encountered in gynecology practice and have malignant potential. It may be asymptomatic in the clinic or may present with abnormal uterine bleeding. Although its pathophysiology has not been clearly revealed, there are many studies in the literature about it. However, the autophagy pathway emerges as a subject that has never been evaluated. In this study, the investigators would like to prospectively evaluate Beclin 1, LC3A / B and p62 markers in the autophagy pathway in endometrial polyp tissue samples by immunohistochemistry and reveal their importance.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients over 35 years of age with a histopathologically confirmed diagnosis of endometrial polyp
  • patients over the age of 35 whose histopathologically reported normal endometrial biopsy results.

Exclusion criteria

  • Are under the age of 35,
  • those with cognitive dysfunction,
  • diagnosed with any type of cancer
  • who are under treatment for cancer,
  • diabetes mellitus,
  • hypertension,
  • endometriosis,
  • adenomyosis,
  • chronic endometritis,
  • have an acute or chronic illness,
  • patients who have smoked and used alcohol in the last 10 years

Treatment and study plan

Beclin 1 gene

Genetic

The determination of Beclin 1, LC3-II and p62 genes, which are evaluated by immunohistochemistry, at the protein level will be done by ELISA method in MSKU Medical Faculty Medical Biology Laboratory.

Other names: LC3-II gene, p62 gene

Primary outcomes

  1. autophagy marker

    Time frame: through study completion, an average of 1 year

    Beclin 1 gene level

  2. autophagy marker

    Time frame: through study completion, an average of 1 year

    LC3II gene level

  3. autophagy marker

    Time frame: through study completion, an average of 1 year

    p62 gene level

Sponsors and collaborators

Lead sponsor

Muğla Sıtkı Koçman University

Other

Registry information

Official study title

Investigation of Autophagy Markers in Endometrial Polyps

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Jan 12, 2021
Registry last updated
Dec 6, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.